

Cover Story
As biomedical research at NIH faces an existential threat from the Trump administration, an entrepreneur is winning over allies for what he describes as a “simple idea” that could introduce a massive new infusion of money for innovation in medicine.
Cancer Policy


In Brief
Clinical Roundup


Drugs & Targets
Trending Stories
- House passes three-year extension of ACA subsidies with bipartisan support
- Nancy Goodman: “Sen. Sanders says he cares about kids with cancer. I’m just asking him to show us.”
- Elisa Rodriguez named first chief diversity and equity officer for faculty at Roswell Park
- Gregory Curt, Clinician and Drug Developer, Dies at 64
- A planned randomized trial will ask an intriguing question: Do COVID vaccines potentiate checkpoint inhibitors?
- Klausner: CRUK Grand Challenge—more than just another grant

















